SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System

N/A Completed NCT02439775

Summary

The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.

Change in Systolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

From baseline to 6 months post-procedure · mm Hg

Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events

From Baseline to 1 month post-procedure (6 months for new renal artery stenosis) · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
• Improving Hypertension Medication Adherence for Older Adults — University of Arizona
• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Ar — Actelion
• LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca
• Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test — Stanford University

All trials